CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical types of antibiotics for the targeting of osteoarticular infectious illnesses. In addition, the nanocapsule encapsulation reduces the risk of tissue irritation from the antibiotics, and improves the pharmacology of antibiotics they convey, including stopping bacterial resistance chlamydia treatment .